Radical changes in multiple sclerosis pathogenesis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 2, 2011, Pages 141-150

  Van Horssen, Jack ^a   Witte, Maarten E ^a   Schreibelt, Gerty ^b   de Vries, Helga E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antioxidants; Multiple sclerosis; Neurodegeneration; Neuroinflammation; Oxidative damage; Reactive oxygen species

Indexed keywords

3 HYDROXYCOUMARIN; BG 00012; CATALASE; FLAVONOID; HEME OXYGENASE 2; NEUROPROTECTIVE AGENT; PEROXIREDOXIN; REACTIVE OXYGEN METABOLITE; SULFORAPHANE; TERT BUTYLHYDROQUINONE; THIOCTIC ACID; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN DAMAGE; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME MECHANISM; HUMAN; MACROPHAGE ACTIVATION; MICROGLIA; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIOXIDANTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FREE RADICALS; HUMANS; MACROPHAGES; MICROGLIA; MITOCHONDRIA; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 78650170203     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.06.011     Document Type: Review

References (140)

1. Cadenas E., Boveris A., Ragan C.I., Stoppani A.O. Production of superoxide radicals and hydrogen peroxide by NADH-ubiquinone reductase and ubiquinol-cytochrome c reductase from beef-heart mitochondria. Arch. Biochem. Biophys. 1977, 180:248.
2. Deby C., Goutier R. New perspectives on the biochemistry of superoxide anion and the efficiency of superoxide dismutases. Biochem. Pharmacol. 1990, 39:399.
3. Fridovich I. The biology of oxygen radicals. Science 1978, 201:875.
4. Beckman J.S. The double-edged role of nitric oxide in brain function and superoxide-mediated injury. J. Dev. Physiol. 1991, 15:53.
5. Droge W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82:47.
6. Forman H.J., Torres M. Redox signaling in macrophages. Mol. Aspects Med. 2001, 22:189.
7. Hampton M.B., Kettle A.J., Winterbourn C.C. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998, 92:3007.
8. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787.
9. Moreira P.I., Santos M.S., Oliveira C.R., Shenk J.C., Nunomura A., Smith M.A., Zhu X., Perry G. Alzheimer disease and the role of free radicals in the pathogenesis of the disease, CNS. Neurol. Disord. Drug Targets 2008, 7:3.
10. Beal M.F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. N.Y. Acad. Sci. 2003, 991:120.
11. Reynolds A., Laurie C., Mosley R.L., Gendelman H.E. Oxidative stress and the pathogenesis of neurodegenerative disorders. Int. Rev. Neurobiol. 2007, 82:297.
12. Bo L., Geurts J.J., Mork S.J., van der Valk P. Grey matter pathology in multiple sclerosis. Acta Neurol. Scand. Suppl. 2006, 183:48.
13. Hafler D.A. Multiple sclerosis. J. Clin. Invest 2004, 113:788.
14. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354:942.
15. Bo L., Vedeler C.A., Nyland H.I., Trapp B.D., Mork S.J. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol. 2003, 62:723.
16. van der Valk P., De Groot C.J. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol. Appl. Neurobiol. 2000, 26:2.
17. Colton C.A., Gilbert D.L. Microglia, an in vivo source of reactive oxygen species in the brain. Adv. Neurol. 1993, 59:321.
18. Gray E., Thomas T.L., Betmouni S., Scolding N., Love S. Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci. Lett. 2008, 444:195.
19. Gray E., Thomas T.L., Betmouni S., Scolding N., Love S. Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol. 2008, 18:86.
20. Bo L., Vedeler C.A., Nyland H., Trapp B.D., Mork S.J. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult. Scler. 2003, 9:323.
21. Block M.L. NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC. Neurosci. 2008, 9(Suppl 2):S8.
22. Rubbo H., Trostchansky A., O'Donnell V.B. Peroxynitrite-mediated lipid oxidation and nitration: mechanisms and consequences. Arch. Biochem. Biophys. 2009, 484:167.
23. Boveris A., Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem. J. 1973, 134:707.
24. Kalman B., Lublin F.D., Alder H. Mitochondrial DNA mutations in multiple sclerosis. Mult. Scler. 1995, 1:32.
25. Olsen N.K., Hansen A.W., Norby S., Edal A.L., Jorgensen J.R., Rosenberg T. Leber's hereditary optic neuropathy associated with a disorder indistinguishable from multiple sclerosis in a male harbouring the mitochondrial DNA 11778 mutation. Acta Neurol. Scand. 1995, 91:326.
26. Kalman B., Lublin F.D., Alder H. Characterization of the mitochondrial DNA in patients with multiple sclerosis. J. Neurol. Sci. 1996, 140:75.
27. Kalman B., Li S., Chatterjee D., O'Connor J., Voehl M.R., Brown M.D., Alder H. Large scale screening of the mitochondrial DNA reveals no pathogenic mutations but a haplotype associated with multiple sclerosis in Caucasians. Acta Neurol. Scand. 1999, 99:16.
28. Kalman B., Alder H. Is the mitochondrial DNA involved in determining susceptibility to multiple sclerosis?. Acta Neurol. Scand. 1998, 98:232.
29. Dutta R., McDonough J., Yin X., Peterson J., Chang A., Torres T., Gudz T., Macklin W.B., Lewis D.A., Fox R.J., Rudick R., Mirnics K., Trapp B.D. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 2006, 59:478.
30. Kalman B., Laitinen K., Komoly S. The involvement of mitochondria in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 2007, 188:1.
31. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120(Pt 3):393.
32. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278.
33. Kornek B., Storch M.K., Weissert R., Wallstroem E., Stefferl A., Olsson T., Linington C., Schmidbauer M., Lassmann H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 2000, 157:267.
34. Craner M.J., Newcombe J., Black J.A., Hartle C., Cuzner M.L., Waxman S.G. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc. Nat. Acad. Sci. U.S.A. 2004, 101:8168.
35. Mahad D.J., Ziabreva I., Campbell G., Lax N., White K., Hanson P.S., Lassmann H., Turnbull D.M. Mitochondrial changes within axons in multiple sclerosis. Brain 2009.
36. Witte M.E., Bo L., Rodenburg R.J., Belien J.A., Musters R., Hazes T., Wintjes L.T., Smeitink J.A., Geurts J.J., de Vries H.E., van der Valk P., van H.J. Enhanced number and activity of mitochondria in multiple sclerosis lesions. J. Pathol. 2009, 2:193.
37. Andrews H.E., Nichols P.P., Bates D., Turnbull D.M. Mitochondrial dysfunction plays a key role in progressive axonal loss in Multiple Sclerosis. Med. Hypotheses 2005, 64:669.
38. Waxman S.G. Ions, energy and axonal injury: towards a molecular neurology of multiple sclerosis. Trends Mol. Med. 2006, 12:192.
39. Gibson C.L., Coughlan T.C., Murphy S.P. Glial nitric oxide and ischemia. Glia 2005, 50:417.
40. Ischiropoulos H., Zhu L., Chen J., Tsai M., Martin J.C., Smith C.D., Beckman J.S. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 1992, 298:431.
41. Qi X., Lewin A.S., Sun L., Hauswirth W.W., Guy J. Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis. J. Biol. Chem. 2006, 281:31950.
42. Qi X., Lewin A.S., Sun L., Hauswirth W.W., Guy J. Suppression of mitochondrial oxidative stress provides long-term neuroprotection in experimental optic neuritis. Invest. Ophthalmol. Vis. Sci. 2007, 48:681.
43. van Meeteren M.E., Teunissen C.E., Dijkstra C.D., van Tol E.A. Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur. J. Clin. Nutr. 2005, 59:1347.
44. Gilgun-Sherki Y., Melamed E., Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 2004, 251:261.
45. Karg E., Klivenyi P., Nemeth I., Bencsik K., Pinter S., Vecsei L. Nonenzymatic antioxidants of blood in multiple sclerosis. J. Neurol. 1999, 246:533.
46. Greco A., Minghetti L., Sette G., Fieschi C., Levi G. Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 1999, 53:1876.
47. Calabrese V., Raffaele R., Cosentino E., Rizza V. Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. Int. J. Clin. Pharmacol. Res. 1994, 14:119.
48. Koch M., Ramsaransing G.S., Arutjunyan A.V., Stepanov M., Teelken A., Heersema D.J., De Keyser J. Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. J. Neurol. 2006, 253:483.
49. Ferretti G., Bacchetti T., Principi F., Di Ludovico F., Viti B., Angeleri V.A., Danni M., Provinciali L. Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult. Scler. 2005, 11:677.
50. Van Horssen J., Schreibelt G., Drexhage J., Hazes T., Dijkstra C.D., Van der Valk P., de Vries H.E. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic. Biol. Med. 2008, 45:1729.
51. Liu J.S., Zhao M.L., Brosnan C.F., Lee S.C. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am. J. Pathol. 2001, 158:2057.
52. Cross A.H., Manning P.T., Keeling R.M., Schmidt R.E., Misko T.P. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J. Neuroimmunol. 1998, 88:45.
53. Diaz-Sanchez M., Williams K., DeLuca G.C., Esiri M.M. Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathol. 2006, 111:289.
54. Lu F., Selak M., O'Connor J., Croul S., Lorenzana C., Butunoi C., Kalman B. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J. Neurol. Sci. 2000, 177:95.
55. Bizzozero O.A., DeJesus G., Bixler H.A., Pastuszyn A. Evidence of nitrosative damage in the brain white matter of patients with multiple sclerosis. Neurochem. Res. 2005, 30:139.
56. Bizzozero O.A., DeJesus G., Callahan K., Pastuszyn A. Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis. J. Neurosci. Res. 2005, 81:687.
57. van der Goes A., Wouters D., Van Der Pol S.M., Huizinga R., Ronken E., Adamson P., Greenwood J., Dijkstra C.D., de Vries H.E. Reactive oxygen species enhance the migration of monocytes across the blood-brain barrier in vitro. FASEB J. 2001, 15:1852.
58. Schreibelt G., Musters R.J., Reijerkerk A., de Groot L.R., van der Pol S.M., Hendrikx E.M., Dopp E.D., Dijkstra C.D., Drukarch B., de Vries H.E. Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity. J. Immunol. 2006, 177:2630.
59. van der Goes A., Brouwer J., Hoekstra K., Roos D., Van den Berg T.K., Dijkstra C.D. Reactive oxygen species are required for the phagocytosis of myelin by macrophages. J. Neuroimmunol. 1998, 92:67.
60. Connor J.R. Iron regulation in the brain at the cell and molecular level. Adv. Exp. Med. Biol. 1994, 356:229.
61. Juurlink B.H., Thorburne S.K., Hertz L. Peroxide-scavenging deficit underlies oligodendrocyte susceptibility to oxidative stress. Glia 1998, 22:371.
62. Baud O., Greene A.E., Li J., Wang H., Volpe J.J., Rosenberg P.A. Glutathione peroxidase-catalase cooperativity is required for resistance to hydrogen peroxide by mature rat oligodendrocytes. J. Neurosci. 2004, 24:1531.
63. Butts B.D., Houde C., Mehmet H. Maturation-dependent sensitivity of oligodendrocyte lineage cells to apoptosis: implications for normal development and disease. Cell Death. Differ. 2008, 15:1178.
64. Blomgren K., Hagberg H. Free radicals, mitochondria, and hypoxia-ischemia in the developing brain. Free Radic. Biol. Med. 2006, 40:388.
65. French H.M., Reid M., Mamontov P., Simmons R.A., Grinspan J.B. Oxidative stress disrupts oligodendrocyte maturation. J. Neurosci. Res. 2009, 14:3076.
66. Kean R.B., Spitsin S.V., Mikheeva T., Scott G.S., Hooper D.C. The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity. J. Immunol. 2000, 165:6511.
67. Hendriks J.J., Alblas J., Van Der Pol S.M., van Tol E.A., Dijkstra C.D., de Vries H.E. Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J. Exp. Med. 2004, 200:1667.
68. Moriya M., Nakatsuji Y., Miyamoto K., Okuno T., Kinoshita M., Kumanogoh A., Kusunoki S., Sakoda S. Edaravone, a free radical scavenger, ameliorates experimental autoimmune encephalomyelitis. Neurosci. Lett. 2008, 440:323.
69. Basso A.S., Frenkel D., Quintana F.J., Costa-Pinto F.A., Petrovic-Stojkovic S., Puckett L., Monsonego A., Bar-Shir A., Engel Y., Gozin M., Weiner H.L. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J. Clin. Invest. 2008, 118:1532.
70. Chaudhary P., Marracci G.H., Bourdette D.N. Lipoic acid inhibits expression of ICAM-1 and VCAM-1 by CNS endothelial cells and T cell migration into the spinal cord in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2006, 175:87.
71. Gilgun-Sherki Y., Barhum Y., Atlas D., Melamed E., Offen D. Analysis of gene expression in MOG-induced experimental autoimmune encephalomyelitis after treatment with a novel brain-penetrating antioxidant. J. Mol. Neurosci. 2005, 27:125.
72. Aktas O., Prozorovski T., Smorodchenko A., Savaskan N.E., Lauster R., Kloetzel P.M., Infante-Duarte C., Brocke S., Zipp F. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol. 2004, 173:5794.
73. Muthian G., Bright J.J. Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte. J. Clin. Immunol. 2004, 24:542.
74. Ilhan A., Akyol O., Gurel A., Armutcu F., Iraz M., Oztas E. Protective effects of caffeic acid phenethyl ester against experimental allergic encephalomyelitis-induced oxidative stress in rats. Free Radic. Biol. Med. 2004, 37:386.
75. Carlson N.G., Rose J.W. Antioxidants in multiple sclerosis: do they have a role in therapy?. CNS. Drugs 2006, 20:433.
76. Itoh K., Wakabayashi N., Katoh Y., Ishii T., O'Connor T., Yamamoto M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells 2003, 8:379.
77. Itoh K., Tong K.I., Yamamoto M. Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic. Biol. Med. 2004, 36:1208.
78. Motohashi H., Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med. 2004, 10:549.
79. Kensler T.W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007, 47:89.
80. McCord J.M., Edeas M.A. SOD, oxidative stress and human pathologies: a brief history and a future vision. Biomed. Pharmacother. 2005, 59:139.
81. Thimmulappa R.K., Mai K.H., Srisuma S., Kensler T.W., Yamamoto M., Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 2002, 62:5196.
82. Kim Y.J., Ahn J.Y., Liang P., Ip C., Zhang Y., Park Y.M. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. Cancer Res. 2007, 67:546.
83. Dringen R., Pawlowski P.G., Hirrlinger J. Peroxide detoxification by brain cells. J. Neurosci. Res. 2005, 79:157.
84. Jaiswal A.K. Regulation of genes encoding NAD(P)H:quinone oxidoreductases. Free Radic. Biol. Med. 2000, 29:254.
85. Tajouri L., Mellick A.S., Ashton K.J., Tannenberg A.E., Nagra R.M., Tourtellotte W.W., Griffiths L.R. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res. Mol. Brain Res. 2003, 119:170.
86. Guy J., Ellis E.A., Hope G.M., Rao N.A. Antioxidant enzyme suppression of demyelination in experimental optic neuritis. Curr. Eye Res. 1989, 8:467.
87. Guy J., Ellis E.A., Hope G.M., Rao N.A. Antioxidant enzymes reduce loss of blood-brain barrier integrity in experimental optic neuritis. Arch. Ophthalmol. 1989, 107:1359.
88. Ruuls S.R., Bauer J., Sontrop K., Huitinga I., 't Hart B.A., Dijkstra C.D. Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J. Neuroimmunol. 1995, 56:207.
89. Guy J., Qi X., Wang H., Hauswirth W.W. Adenoviral gene therapy with catalase suppresses experimental optic neuritis. Arch. Ophthalmol. 1999, 117:1533.
90. Guy J., Qi X., Hauswirth W.W. Adeno-associated viral-mediated catalase expression suppresses optic neuritis in experimental allergic encephalomyelitis. Proc. Nat. Acad. Sci. U.S.A. 1998, 95:13847.
91. Sarafian T.A., Verity M.A., Vinters H.V., Shih C.C., Shi L., Ji X.D., Dong L., Shau H. Differential expression of peroxiredoxin subtypes in human brain cell types. J. Neurosci. Res. 1999, 56:206.
92. Schreibelt G., van H.J., Haseloff R.F., Reijerkerk A., van der Pol S.M., Nieuwenhuizen O., Krause E., Blasig I.E., Dijkstra C.D., Ronken E., de Vries H.E. Protective effects of peroxiredoxin-1 at the injured blood-brain barrier. Free Radic. Biol. Med. 2008, 45:256.
93. Krapfenbauer K., Engidawork E., Cairns N., Fountoulakis M., Lubec G. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 2003, 967:152.
94. Wagener F.A., Volk H.D., Willis D., Abraham N.G., Soares M.P., Adema G.J., Figdor C.G. Different faces of the heme-heme oxygenase system in inflammation. Pharmacol. Rev. 2003, 55:551.
95. Hung S.Y., Liou H.C., Kang K.H., Wu R.M., Wen C.C., Fu W.M. Overexpression of heme oxygenase-1 protects dopaminergic neurons against 1-methyl-4-phenylpyridinium-induced neurotoxicity. Mol. Pharmacol. 2008, 74:1564.
96. Takata K., Kitamura Y., Kakimura J., Shibagaki K., Taniguchi T., Gebicke-Haerter P.J., Smith M.A., Perry G., Shimohama S. Possible protective mechanisms of heme oxygenase-1 in the brain. Ann. N.Y. Acad. Sci. 2002, 977:501.
97. Chora A.A., Fontoura P., Cunha A., Pais T.F., Cardoso S., Ho P.P., Lee L.Y., Sobel R.A., Steinman L., Soares M.P. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J. Clin. Invest. 2007, 117:438.
98. Liu Y., Zhu B., Luo L., Li P., Paty D.W., Cynader M.S. Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis. Neuroreport 2001, 12:1841.
99. Chakrabarty A., Emerson M.R., LeVine S.M. Heme oxygenase-1 in SJL mice with experimental allergic encephalomyelitis. Mult. Scler. 2003, 9:372.
100. Stahnke T., Stadelmann C., Netzler A., Bruck W., Richter-Landsberg C. Differential upregulation of heme oxygenase-1 (HSP32) in glial cells after oxidative stress and in demyelinating disorders. J. Mol. Neurosci. 2007, 32:25.
101. Mehindate K., Sahlas D.J., Frankel D., Mawal Y., Liberman A., Corcos J., Dion S., Schipper H.M. Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis. J. Neurochem. 2001, 77:1386.
102. Emerson M.R., LeVine S.M. Heme oxygenase-1 and NADPH cytochrome P450 reductase expression in experimental allergic encephalomyelitis: an expanded view of the stress response. J. Neurochem. 2000, 75:2555.
103. Liu Y., Zhu B., Wang X., Luo L., Li P., Paty D.W., Cynader M.S. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J. Neuroimmunol. 2003, 139:27.
104. Liu Y., Liu J., Tetzlaff W., Paty D.W., Cynader M.S. Biliverdin reductase, a major physiologic cytoprotectant, suppresses experimental autoimmune encephalomyelitis. Free Radic. Biol. Med. 2006, 40:960.
105. Siegel D., Gustafson D.L., Dehn D.L., Han J.Y., Boonchoong P., Berliner L.J., Ross D. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol. Pharmacol. 2004, 65:1238.
106. Ross D., Kepa J.K., Winski S.L., Beall H.D., Anwar A., Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem. Biol. Interact. 2000, 129:77.
107. Siegel D., Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic. Biol. Med. 2000, 29:246.
108. Schultzberg M., Segura-Aguilar J., Lind C. Distribution of DT diaphorase in the rat brain: biochemical and immunohistochemical studies. Neuroscience 1988, 27:763.
109. van Horssen J., Schreibelt G., Bo L., Montagne L., Drukarch B., van Muiswinkel F.L., de Vries H.E. NAD(P)H:quinone oxidoreductase 1 expression in multiple sclerosis lesions. Free Radic. Biol. Med. 2006, 41:311.
110. Cross A.H., Manning P.T., Keeling R.M., Schmidt R.E., Misko T.P. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J. Neuroimmunol. 1998, 88:45.
111. Qi X., Guy J., Nick H., Valentine J., Rao N. Increase of manganese superoxide dismutase, but not of Cu/Zn-SOD, in experimental optic neuritis. Invest. Ophthalmol. Vis. Sci. 1997, 38:1203.
112. Mari M., Morales A., Colell A., Garcia-Ruiz C., Fernandez-Checa J.C. Mitochondrial glutathione, a key survival antioxidant. Antioxid. Redox. Signal. 2009, 11:2685.
113. Patenaude A., Murthy M.R., Mirault M.E. Emerging roles of thioredoxin cycle enzymes in the central nervous system. Cell Mol. Life Sci. 2005, 62:1063.
114. Holley J.E., Newcombe J., Winyard P.G., Gutowski N.J. Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes. Mult. Scler. 2007, 13:955.
115. Hattori F., Murayama N., Noshita T., Oikawa S. Mitochondrial peroxiredoxin-3 protects hippocampal neurons from excitotoxic injury in vivo. J. Neurochem. 2003, 86:860.
116. Plaisant F., Clippe A., Vander S.D., Knoops B., Gressens P. Recombinant peroxiredoxin 5 protects against excitotoxic brain lesions in newborn mice. Free Radic. Biol. Med. 2003, 34:862.
117. Karunakaran S., Saeed U., Ramakrishnan S., Koumar R.C., Ravindranath V. Constitutive expression and functional characterization of mitochondrial glutaredoxin (Grx2) in mouse and human brain. Brain Res. 2007, 1185:8.
118. Sims N.R., Nilsson M., Muyderman H. Mitochondrial glutathione: a modulator of brain cell death. J. Bioenerg. Biomembr. 2004, 36:329.
119. Wullner U., Seyfried J., Groscurth P., Beinroth S., Winter S., Gleichmann M., Heneka M., Loschmann P., Schulz J.B., Weller M., Klockgether T. Glutathione depletion and neuronal cell death: the role of reactive oxygen intermediates and mitochondrial function. Brain Res. 1999, 826:53.
120. Kelso G.F., Porteous C.M., Coulter C.V., Hughes G., Porteous W.K., Ledgerwood E.C., Smith R.A., Murphy M.P. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J. Biol. Chem. 2001, 276:4588.
121. Smith R.A., Porteous C.M., Coulter C.V., Murphy M.P. Selective targeting of an antioxidant to mitochondria. Eur. J. Biochem. 1999, 263:709.
122. Chen K., Thomas S.R., Albano A., Murphy M.P., Keaney J.F. Mitochondrial function is required for hydrogen peroxide-induced growth factor receptor transactivation and downstream signaling. J. Biol. Chem. 2004, 279:35079.
123. Dhanasekaran A., Kotamraju S., Kalivendi S.V., Matsunaga T., Shang T., Keszler A., Joseph J., Kalyanaraman B. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J. Biol. Chem. 2004, 279:37575.
124. Saretzki G., Murphy M.P., von Z.T. MitoQ counteracts telomere shortening and elongates lifespan of fibroblasts under mild oxidative stress. Aging Cell 2003, 2:141.
125. Siler-Marsiglio K.I., Pan Q., Paiva M., Madorsky I., Khurana N.C., Heaton M.B. Mitochondrially targeted vitamin E and vitamin E mitigate ethanol-mediated effects on cerebellar granule cell antioxidant defense systems. Brain Res. 2005, 1052:202.
126. Smith R.A., Porteous C.M., Gane A.M., Murphy M.P. Delivery of bioactive molecules to mitochondria in vivo. Proc. Nat. Acad. Sci. U.S.A. 2003, 100:5407.
127. Graham D., Huynh N.N., Hamilton C.A., Beattie E., Smith R.A., Cocheme H.M., Murphy M.P., Dominiczak A.F. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 2009, 54:322.
128. Adlam V.J., Harrison J.C., Porteous C.M., James A.M., Smith R.A., Murphy M.P., Sammut I.A. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J. 2005, 19:1088.
129. Covey M.V., Murphy M.P., Hobbs C.E., Smith R.A., Oorschot D.E. Effect of the mitochondrial antioxidant, Mito Vitamin E, on hypoxic-ischemic striatal injury in neonatal rats: a dose-response and stereological study. Exp. Neurol. 2006, 199:513.
130. Wierinckx A., Breve J., Mercier D., Schultzberg M., Drukarch B., Van Dam A.M. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J. Neuroimmunol. 2005, 166:132.
131. Nguyen T., Sherratt P.J., Pickett C.B. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu. Rev. Pharmacol. Toxicol. 2003, 43:233.
132. Shih A.Y., Imbeault S., Barakauskas V., Erb H., Jiang L., Li P., Murphy T.H. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J. Biol. Chem. 2005, 280:22925.
133. Shih A.Y., Li P., Murphy T.H. A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J. Neurosci. 2005, 25:10321.
134. Zhao J., Kobori N., Aronowski J., Dash P.K. Sulforaphane reduces infarct volume following focal cerebral ischemia in rodents. Neurosci. Lett. 2006, 393:108.
135. Zhao J., Moore A.N., Redell J.B., Dash P.K. Enhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injury. J. Neurosci. 2007, 27:10240.
136. Yang C., Zhang X., Fan H., Liu Y. Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res. 2009, 1282:133.
137. Dash P.K., Zhao J., Orsi S.A., Zhang M., Moore A.N. Sulforaphane improves cognitive function administered following traumatic brain injury. Neurosci. Lett. 2009, 460:103.
138. Innamorato N.G., Rojo A.I., Garcia-Yague A.J., Yamamoto M., de Ceballos M.L., Cuadrado A. The transcription factor Nrf2 is a therapeutic target against brain inflammation. J. Immunol. 2008, 181:680.
139. Chen X.L., Varner S.E., Rao A.S., Grey J.Y., Thomas S., Cook C.K., Wasserman M.A., Medford R.M., Jaiswal A.K., Kunsch C. Laminar flow induction of antioxidant response element-mediated genes in endothelial cells. A novel anti-inflammatory mechanism. J. Biol. Chem. 2003, 278:703.
140. Chen X.L., Dodd G., Kunsch C. Sulforaphane inhibits TNF-alpha-induced activation of p38 MAP kinase and VCAM-1 and MCP-1 expression in endothelial cells. Inflamm. Res. 2009, 8:513.